Inhibitory Effects of Enterolactone on Growth and Metastasis in Human Breast Cancer

Nutrition and Cancer

Volumn 67, Issue 8, 2015, Pages 1326-1334

  Xiong, Xiang Yang ^a   Hu, Xiao Juan ^a   Li, Yong ^a   Liu, Cheng Mei ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A2; CYCLIN B1; CYCLIN B2; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; CYCLIN E1; CYCLINE; ENTEROLACTONE; KI 67 ANTIGEN; MESSENGER RNA; PAXILLIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG; 2,3-BIS(3'-HYDROXYBENZYL)BUTYROLACTONE; FOCAL ADHESION KINASE 1; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; GAMMA BUTYROLACTONE; LIGNAN; PTK2 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSKELETON; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; MDA MB 231 CELL LINE; METASTASIS; PROTEIN PHOSPHORYLATION; ANALOGS AND DERIVATIVES; BREAST TUMOR; CELL CYCLE; DRUG EFFECTS; GENETICS; NEOPLASM METASTASIS; PATHOLOGY; PREVENTION AND CONTROL; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

4-BUTYROLACTONE; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLINS; CYTOSKELETON; FOCAL ADHESION KINASE 1; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HUMANS; KI-67 ANTIGEN; LIGNANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PAXILLIN; PROLIFERATING CELL NUCLEAR ANTIGEN; RNA, MESSENGER; S PHASE; SIGNAL TRANSDUCTION;

EID: 84948715919     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2015.1082113     Document Type: Article

References (38)

1. Adlercreutz H and Mazur W: Phyto-oestrogens and Western diseases. Annals of Medicine 29, 95-120, 1997.
2. Touillaud MS, Thiebaut AC, Fournier A, Niravong M, Boutron-Ruault MC, et al.: Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status. Journal of the National Cancer Institute 99, 475-486, 2007.
3. Adlercreutz H: Lignans and human health. Critical Reviews in Clinical Laboratory Sciences 44, 483-525, 2007.
4. McCann SE, Thompson LU, Nie J, Dorn J, Trevisan M, et al.: Dietary lignan intakes in relation to survival among women with breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Research and Treatment 122, 229-235, 2010.
5. Raffaelli B, Hoikkala A, Leppala E, and Wahala K: Enterolignans. Journal of Chromatography: B. Analytical Technologies in the Biomedical and Life Sciences 777, 29-43, 2002.
6. Lampe JW, Atkinson C, and Hullar MA: Assessing exposure to lignans and their metabolites in humans. Journal of AOAC International 89, 1174-1181, 2006.
7. Penalvo JL, Heinonen SM, Aura AM, and Adlercreutz H: Dietary sesamin is converted to enterolactone in humans. The Journal of Nutrition 135, 1056-1062, 2005.
8. Bergman Jungestrom M, Thompson LU, and Dabrosin C: Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13, 1061-1067, 2007.
9. Saarinen NM, Abrahamsson A, and Dabrosin C: Estrogen-induced angiogenic factors derived from stromal and cancer cells are differently regulated by enterolactone and genistein in human breast cancer in vivo. International Journal of Cancer/Journal international du cancer 127, 737-745, 2010.
10. Chen J and Thompson, LU: Lignans and tamoxifen, alone or in combination, reduce human breast cancer cell adhesion, invasion and migration in vitro. Breast Cancer Research and Treatment 80, 163-170, 2003.
11. Guglielmini P, Rubagotti A, and Boccardo F: Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. Breast Cancer Research and Treatment 132, 661-668. 2012.
12. Seibold P, Vrieling A, Johnson TS, Buck K, Behrens S, et al: Enterolactone concentrations and prognosis after postmenopausal breast cancer: assessment of effect modification and meta-analysis. International Journal of Cancer/Journal international du cancer 135, 923-933, 2014.
13. Buck K, Vrieling A, Zaineddin AK, Becker S, Husing A, et al.: Serum enterolactone and prognosis of postmenopausal breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 29, 3730-3738, 2011.
14. Chen J, Stavro PM, and Thompson LU: Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor. Nutrition and Cancer 43, 187-192, 2002.
15. Wang L, Chen J, and Thompson LU: The inhibitory effect of flaxseed on the growth and metastasis of estrogen receptor negative human breast cancer xenograftsis attributed to both its lignan and oil components. International Journal of Cancer/Journal international du cancer 116, 793-798, 2005.
16. Li D, Yee JA, Thompson LU, and Yan L: Dietary supplementation with secoisolariciresinol diglycoside (SDG) reduces experimental metastasis of melanoma cells in mice. Cancer Letters 142, 91-96, 1999.
17. Miura D, Saarinen NM, Miura Y, Santti R, and Yagasaki K: Hydroxymatairesinol and its mammalian metabolite enterolactone reduce the growth and metastasis of subcutaneous AH109A hepatomas in rats. Nutrition and Cancer 58, 49-59, 2007.
18. Xiong X, Wang Y, Liu C, Lu Q, Liu T, et al: Heat shock protein 90beta stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells. Experimental Cell Research 326, 78-89, 2014.
19. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, et al: Rasand PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. The Journal of Clinical Investigation 119, 252-266, 2009.
20. Etienne-Manneville S: Actin and microtubules in cell motility: which one is in control? Traffic 5, 470-477, 2004.
21. Prasad K: Antioxidant activity of secoisolariciresinol diglucoside-derived metabolites, secoisolariciresinol, enterodiol, and enterolactone. The International Journal of Angiology: Official Publication of the International College of Angiology 9, 220-225, 2000.
22. Chen LH, Fang J, Li H, Demark-Wahnefried W, Lin X, et al: Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated, caspase-dependent pathway. Molecular Cancer Therapeutics 6, 2581-2590, 2007.
23. Omar WS, Eissa S, Moustafa H, Farag H, Ezzat I, et al: Role of thallium-201 chloride and Tc-99m methoxy-isobutyl-isonitrite (sestaMIBI) in evaluation of breast masses: correlation with the immunohistochemical characteristic parameters (Ki-67, PCNA, Bcl, and angiogenesis) in malignant lesions. Anticancer Research 17, 1639-1644, 1997.
24. Kushlinskii NE, Orinovskii MB, Gurevich LE, Kazantseva IA, Talaeva ShZh, et al: Expression of biomolecular markers (Ki-67, PCNA, Bcl-2, BAX, BclX, VEGF) in breast tumors. Bulletin of Experimental Biology and Medicine 137, 182-185, 2004.
25. Wonsey DR and Follettie MT: Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Research 65, 5181-5189, 2005.
26. Wierstra I and J Alves: FOXM1, a typical proliferation-associated transcription factor. Biological Chemistry 388, 1257-1274, 2007.
27. Gemenetzidis E, Bose A, Riaz AM, Chaplin T, Young BD, et al: FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PloS One 4, e4849, 2009.
28. Raychaudhuri P and Park HJ: FoxM1: a master regulator of tumor metastasis. Cancer Research 71, 4329-4333, 2011.
29. Vermeulen K, Van Bockstaele DR, and Berneman ZN: The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Proliferation 36, 131-149, 2003.
30. McCann MJ, Gill CI, Linton T, Berrar D, McGlynn H, et al: Enterolactone restricts the proliferation of the LNCaP human prostate cancer cell line in vitro. Molecular Nutrition & Food Research 52, 567-580, 2008.
31. Hanks SK, Ryzhova L, Shin NY, and Brabek J: Focal adhesion kinase signaling activities and their implications in the control of cell survival andmotility. Frontiers in Bioscience: A Journal and Virtual Library 8, d982-d996, 2003.
32. Mitra SK, Hanson DA, and Schlaepfer DD: Focal adhesion kinase: in command and control of cell motility. Nature Reviews: Molecular Cell Biology 6, 56-68, 2005.
33. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, et al: The role of focal-adhesion kinase in cancer: a new therapeutic opportunity. Nature Reviews: Cancer 5, 505-515, 2005.
34. Cance WG, Harris JE, Iacocca MV, Roche E, Yang X, et al: Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 6, 2417-2423, 2000.
35. Lietha D, Cai X, Ceccarelli DF, Li Y, Schaller MD, et al: Structural basis for the autoinhibition of focal adhesion kinase. Cell 129, 1177-1187, 2007.
36. Deakin NO and Turner CE: Paxillin comes of age. Journal of Cell Science 121(Pt 15), 2435-2444, 2008.
37. Schaller MD and Parsons JT: pp125FAK-dependent tyrosine phosphorylation of paxillin creates a high-affinity binding site for Crk. Molecular and Cellular Biology 15, 2635-2645, 1995.
38. Burridge K, CE Turner, and LH Romer: Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. The Journal of Cell Biology 119, 893-903, 1992.